press center press release

Nasdaq Welcomes BeyondSpring Inc. (Nasdaq: BYSI) to The Nasdaq Stock Market


NEW YORK, March 09, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (Nasdaq:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, visited the Nasdaq MarketSite in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market. 

“Today marks an important milestone for BeyondSpring, as we are taking another step in making groundbreaking, easily accessible and affordable treatments available for patients all over the world,” said Lan Huang, Ph.D., Co-Founder, Chairman & CEO, BeyondSpring. “BeyondSpring’s innovative approach to both the science and business of immuno-oncology raises the bar for the biopharma industry. Plinabulin’s well-defined mechanism of action is both promising and desirable as we progress through clinic and move closer to bringing it to market.”

“Innovation has always been a vital part of Nasdaq’s heritage, and we are proud to be the exchange partner of disruptive forces in the health care industry,” said Joe Brantuk, Vice President, Listing Services, Nasdaq. “We congratulate BeyondSpring’s listing today and look forward to supporting the company with a dedicated Nasdaq team and resources as BeyondSpring continues to develop multiple therapeutic candidates for a variety of cancers.” 

BeyondSpring’s lead asset, Plinabulin, is a novel small molecule that has a well-defined mechanism of action, which enables it to alter the tumor micro-environment while inducing dendritic cell maturation and T-cell activation, contributing to Plinabulin's anti-cancer efficacies. It can also reduce severe Neutropenia, a common and potentially life-threatening adverse effect of chemotherapy agents.

BeyondSpring has a robust pipeline from internal development and from collaboration with the Fred Hutchinson Cancer Research Center and University of Washington. The Company’s experienced management team has also brought a combined 30+ drugs to market.

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information about the company is provided by the company or comes from the company’s public filings and is not independently verified by Nasdaq.  Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

About Nasdaq

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables clients to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 85 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,800 listed companies with a market value of $10.1 trillion and approximately 18,000 corporate clients. To learn more, visit:


In This Story


Nasdaq Press Center

Read the latest press releases, request a press kit, and get in touch with our press team.

learn more